surabgene lomparvovec
AXP000257.1 · Viral vector gene therapy
- Platform
- AAV8 vector (NAV)
- Originator
- REGENXBIO
- Sponsor
- AbbVie
Names
| Name | Type | Source |
|---|---|---|
| surabgene lomparvovec | preferred name | curator |
| ABBV-RGX-314 | code | ctgov |
| sura-vec | synonym | ctgov |
| RGX-314 | former code | ctgov |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus 8
- Strain
- AAV8
- Replication
- non replicating
- Modifications
- NAV vector encoding an anti-VEGF antibody fragment
- Transgenes
- anti-VEGF Fab (ranibizumab-like)
- Route
- subretinal, suprachoroidal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07592273 | Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema | Recruiting | Phase 2/3 | 2026-06-01 | 2028-06 | 576 | Diabetic Retinopathy |
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Recruiting | Phase 3 | 2025-11-05 | 2033-03 | 561 | Neovascular Age-related Macular Degeneration |
| NCT06942520 | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) | Recruiting | Phase 2 | 2025-03-18 | 2027-12 | 18 | Diabetic Macular Edema |
| NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Active not recruiting | Phase 3 | 2022-01-13 | 2026-10 | 735 | AMD; CNV; Wet Age-related Macular Degeneration; WetAMD; nAMD; wAMD |
| NCT04832724 | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | Completed | Phase 2 | 2021-02-22 | 2023-10-02 | 60 | Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration; Wet Macular Degeneration |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | Active not recruiting | Phase 2/3 | 2020-12-29 | 2026-12 | 671 | AMD; CNV; Choroidal Neovascularization; Neovascular AMD; Neovascular Age-related Macular Degeneration; Wet AMD; Wet Age-related Macular Degeneration; nAMD; wAMD |
| NCT04567550 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Active not recruiting | Phase 2 | 2020-11-20 | 2026-06-18 | 139 | Center-Involved Diabetic Macular Edema (CI-DME); Diabetic Retinopathy (DR) |
| NCT04514653 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Active not recruiting | Phase 2 | 2020-08-25 | 2026-08 | 146 | Neovascular Age-Related Macular Degeneration (nAMD) |
| NCT03999801 | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | Enrolling by invitation | Phase 2 | 2019-05-31 | 2028-12 | 865 | Neovascular Age-related Macular Degeneration; Wet Macular Degeneration |
| NCT03066258 | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | Completed | Phase 1/2 | 2017-03-29 | 2019-11-24 | 42 | Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT05296447 | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy | Active not recruiting | Phase 2 | 2022-04-04 | 2031-06 | 103 | Diabetic Retinopathy, DR | name in title: RGX-314 |
| NCT05210803 | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD | Enrolling by invitation | Phase 2 | 2021-12-20 | 2031-07 | 116 | Neovascular Age-Related Macular Degeneration (nAMD) | name in title: RGX-314 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38554726 | Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. | Lancet (London, England) | 2024 | cited by trial NCT03066258 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41490387 | Emerging solutions for neovascular age-related macular degeneration. | Current opinion in ophthalmology | 2026 | name in abstract: ABBV-RGX-314 |
| PMID 41688763 | AAV-based gene therapies for neovascular AMD. | Gene therapy | 2026 | name in abstract: RGX-314 |
| PMID 39379521 | Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. | Eye (London, England) | 2025 | name in abstract: RGX-314 |
| PMID 40293479 | Gene therapy in neovascular age related macular degeneration: an update. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie | 2025 | name in abstract: RGX-314 |
| PMID 40319468 | Beyond the injection: delivery systems reshaping retinal disease management. | Expert opinion on pharmacotherapy | 2025 | name in abstract: ABBV-RGX-314 |
| PMID 40364236 | Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update. | Journal of clinical medicine | 2025 | name in abstract: ABBV-RGX-314 |
| PMID 40601510 | Gene Therapy in Age-related Macular Degeneration. | International ophthalmology clinics | 2025 | name in abstract: RGX-314 |
| PMID 41042032 | Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes. | Translational vision science & technology | 2025 | name in title: ABBV-RGX-314 |
| PMID 38330506 | Advancements in the treatment of age-related macular degeneration: a comprehensive review. | Postgraduate medical journal | 2024 | name in abstract: RGX-314 |
| PMID 38927656 | Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. | Genes | 2024 | name in abstract: ABBV-RGX-314 |
| PMID 35017696 | Review of gene therapies for age-related macular degeneration. | Eye (London, England) | 2022 | name in abstract: RGX-314 |
| PMID 35962560 | Investigational drugs in clinical trials for macular degeneration. | Expert opinion on investigational drugs | 2022 | name in abstract: RGX-314 |
| PMID 33671815 | Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. | Pharmaceutics | 2021 | name in abstract: RGX-314 |
| PMID 34188445 | Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. | Drug design, development and therapy | 2021 | name in abstract: RGX-314 |
| PMID 32511123 | Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. | Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) | 2020 | name in abstract: RGX-314 |
| PMID 31298960 | Innovative therapies for neovascular age-related macular degeneration. | Expert opinion on pharmacotherapy | 2019 | name in abstract: RGX-314 |
| PMID 31408444 | AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. | The Journal of clinical investigation | 2019 | name in abstract: RGX-314 |
Notes
NAV AAV8 vector encoding a ranibizumab-like anti-VEGF antibody fragment for neovascular age-related macular degeneration, given subretinally in the pivotal trials (ATMOSPHERE NCT04704921, NCT05407636) and suprachoroidally in others. `targets` is empty: the transgene is an antibody fragment, not a human gene, so no HGNC symbol applies.
How to cite
surabgene lomparvovec (AXP000257.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000257.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.